Top

Published in:

01-06-2003 | Original Research Article

Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers

Authors: Konstanze Diefenbach, Frank Donath, Agathe Maurer, Sabine Quispe Bravo, Klaus-Dieter Wernecke, Dr Ulrich Schwantes, Jutta Haselmann, Ivar Roots

Published in: Clinical Drug Investigation | Issue 6/2003

Abstract

Objective: Central nervous effects of oral anticholinergics may limit the success of incontinence therapy and patient compliance. Only a few studies investigating this topic are available. This study was conducted to determine whether oral anticholinergics alter sleep and psychometric test parameters.

Design: Randomised, double-blind, crossover, placebo-controlled study.

Study participants: 24 healthy volunteers (age 22–36 years) without sleeprelated problems.

Interventions: Polysomnographic recordings, sleep questionnaires and psychometric tests (the number combination test [Zahlen-Verbindungs Test; ZVT] and the d2 attention test) were performed following single doses of oxybutynin 15mg, tolterodine 4mg, trospium chloride 45mg or placebo, each separated by an 8-day washout period.

Results: Rapid eye movement (REM) sleep (relative to total sleep time) was the primary parameter of polysomnography. The REM sleep for oxybutynin was significantly lower than that for trospium chloride (18.4% vs 20.2%; p < 0.05) and lower than that for placebo (20.1%; ns). The number combination test (ZVT), the primary parameter of cognitive function, and the d2 test did not reveal any differences in reaction time. With regard to the other sleep parameters, the REM latency for oxybutynin was clearly higher than that for placebo, trospium chloride and tolterodine. Effects on non-REM sleep were observed only after administration of oxybutynin compared with placebo.

Conclusions: Oxybutynin influenced sleep structure, as was reflected by REM suppression and mild sedation, while subjective parameters and psychometric tests remained unaffected. The sleep and psychometric test values for tolterodine and trospium chloride were comparable to those of placebo. The clinical relevance of these effects is small in healthy young volunteers, but these results cannot be extended to the elderly.

¹The use of tradenames is for product identification only and does not imply endorsement.

McGrother C, Resnick M, Yalla SV, et al. Epidemiology and etiology of urinary incontinence in the elderly. World J Urol 1998; 16 Suppl. 1: S3–9PubMedCrossRef

Schwantes U, Topfmeier P. Importance of pharmacological and physiochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia: chances for improvement of therapy. Int J Clin Pharmacol Ther 1999; 37(5): 209–18PubMed

Fiisgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000; 38(5): 223–34CrossRef

Nies AS, Spielberg SP. Principle of therapeutics. In: Hardman JG et al., editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 43–62

Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46(1): 8–13PubMed

Herberg KW. Alltags-und Verkehrssicherheit unter Inkontinenz-Medikation: Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika. Med Welt 1999; 50: 217–22

British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 34. London: BMA.RPS, 1997

Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337–43PubMedCrossRef

Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315(7119): 1363–4PubMedCentralPubMedCrossRef

10.

InT’Veld BA, Kwee-Zuiderwijk WJM, Van Puijenbroek EP, et al. Neuropsychiatrische bijwerkingen toegeschreven aan her gebruik van oxybutynin. Ned Tijschr Geneeskd 1998; 142(11): 590–2

11.

Valsecia ME, Malgor LA, Espindola JH, et al. New adverse effect of oxybutynin: “night terror” [letter]. Ann Pharmacother 1998; 32(4): 506PubMedCrossRef

12.

Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50(6A Suppl. ): 90–9PubMedCrossRef

13.

Guay DRP. Tolterodine, a new antimuscarinic drag for treatment of bladder overactivity. Pharmacotherapy 1999; 19(3): 267–80PubMedCrossRef

14.

Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drag absorption, distribution, and elimination: principle of therapeutics. In: Hardman JG et al., editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 3–28

15.

Bradbury MW. History and physiology of the blood-brain barrier in relation to delivery of drugs to the brain. In: Begley DJ, Bradbury MW, Kreuter J, editors. The blood-brain barrier and drug delivery to the CNS. New York: Marcel Dekker, 2000: 1–8

16.

Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001; 22(8): 409–14PubMedCrossRef

17.

Chappie CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55(5A Suppl. ): 33–46CrossRef

18.

Shiromani PJ, Gillin JC, Henriksen S. Acetylcholine and the regulation of REM sleep: basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol 1987; 27: 137–56PubMedCrossRef

19.

Velazquez-Moctezuma J, Shalauta M, Gillin JC, et al. Cholinergic antagonists and REM sleep generation. Brain Res 1991; 541: 175–9CrossRef

20.

Hohagen F, Lis S, Riemann D, et al. Influence of biperiden and bomaprine on sleep in healthy subjects. Neuropsychopharmacology 1994; 11(1): 29–32PubMedCrossRef

21.

Vorderholzer U, Hornyak M, Berger M, et al. Antidepressiva. In: Schulz H, editor. DGSM. Ecomed, Landsberg/Lech. Kompendium Schlafmedizin. 1997: XI-2.3

22.

Sagales T, Erill S, Domino EF. Effects of repeated doses of scopolamine on the electroencephalographic stages of sleep in normal volunteers. Clin Pharmacol Ther 1975; 18(6): 727–32PubMed

23.

Sitaram N, Moore AM, Gillin JC. Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist. Nature 1978; 274: 490–2PubMedCrossRef

24.

Poland RE, Tondo L, Rubin RT, et al. Differential effects of scopolamine on nocturnal cortisol secretion, sleep architecture, and REM latency in normal volunteers: relation to sleep and cortisol in depression. Biol Psychiatry 1989; 25: 403–12PubMedCrossRef

25.

McCracken JT, Poland RE, Lutchmansingh P, et al. Sleep electroencephalographic abnormalities in adolescent depressives: effects of scopolamine. Biol Psychiatry 1997; 42: 577–84PubMedCrossRef

26.

Fachinformationsverzeichnis Deutschland. BPI Service GmbH, Frankfurt, Internet: http://www.fachinfo.de

27.

Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human sleep subjects. Washington (DC): US Government Printing Office, 1968

28.

Oswald WD, Roth E. Der Zahlen-Verbindungs-Test. In: Testkatalog 2000/2001. Testzentrale, Göttingen, Bern: Hogrefe-Verlag, 2000: 35

29.

Brickenkamp R, Zillner E. The d2 Test of Attention (d2). In: Testkatalog 2000/2001. Testzentrale, Göttingen, Bern: Hogrefe-Verlag, 2000: 60

30.

Hiller E. Über den statistischen Vergleich mehrerer abhängiger Stichproben: Friedman-Test und d_ij —Test von Wilcoxon und Wilcox. Z Ärztl Fortbild 1988; 82: 885–6

31.

Wemecke KD. Abhängige Stichproben: Friedman-Test. In: Angewandte Statistik für die Praxis. Bonn: Addison-Wesley, 1995: 107–8

32.

Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981: 212–36

33.

Riemann D, Hohagen F, Bahro M, et al. Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86. Em Arch Psychiatry Clin Neurosci 1994; 243: 279–90CrossRef

34.

Alloussi S, Laval K-U, Eckert R, et al. Trospium chloride in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J Clin Res 1998; 1: 439–1

35.

Cardozo L, Chappie CR, Tooz-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. Br J Urol Intern 2000; 85: 659–64CrossRef

36.

Tapp AJS, Cardozo LD, Versi E, et al. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521–6PubMedCrossRef

37.

Thüroff JW, Bunke B, Ebner A, et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813–7PubMed

38.

Ulshöfer B, Bihr AM, Bödeker R-H, et al. Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clin Drug Invest 2001; 21: 563–9CrossRef

Title: Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers
Authors: Konstanze Diefenbach
Frank Donath
Agathe Maurer
Sabine Quispe Bravo
Klaus-Dieter Wernecke
Dr Ulrich Schwantes
Jutta Haselmann
Ivar Roots
Publication date: 01-06-2003
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 6/2003
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200323060-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2003

Consensus on Drug Treatment, Definition and Diagnosis for Insomnia

RETRACTED ARTICLE: Prevention of Nausea and Vomiting with Ramosetron after Total Hip Replacement

Salivary Flow Rates and Pharmacokinetics in Healthy Japanese and Caucasian Volunteers Administered Oral Pilocarpine

Dermatomycoses of the Glabrous Skin